BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 16916865)

  • 1. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
    Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
    J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
    Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
    Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimony-induced cerebellar ataxia.
    Khalil EA; Ahmed AE; Musa AM; Hussein MH
    Saudi Med J; 2006 Jan; 27(1):90-2. PubMed ID: 16432602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
    Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan.
    Adam GK; Abdulla MA; Ahmed AA; Adam I
    Int J Gynaecol Obstet; 2009 Dec; 107(3):208-10. PubMed ID: 19766208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis and pregnancy: analysis of cases reported in a central-western region of Brazil.
    Figueiró-Filho EA; El Beitune P; Queiroz GT; Somensi RS; Morais NO; Dorval ME; Quintana SM; Duarte G
    Arch Gynecol Obstet; 2008 Jul; 278(1):13-6. PubMed ID: 18087708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
    Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
    Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.
    Mueller M; Ritmeijer K; Balasegaram M; Koummuki Y; Santana MR; Davidson R
    Trans R Soc Trop Med Hyg; 2007 Jan; 101(1):19-24. PubMed ID: 16730363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
    Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
    Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E
    J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
    Giri OP; Singh AN
    J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.